Nanobiotix

Nanobiotix EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nanobiotix (NBTX) as of Oct 24, 2026 is -15.94 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -77.56 M USD — a change of -79.45% (higher).

EBITDA

-15.94 MUSD

YoY

-79.45%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nanobiotix is 2025 -15.94 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nanobiotix was 2024 -77.56 M USD. It decreases by -79.45% higher compared to the previous year.

The Nanobiotix EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-34.10 M USD
Jan 1, 2019
-53.05 M USD
Jan 1, 2020
-41.31 M USD
Jan 1, 2021
-59.63 M USD
Jan 1, 2022
-51.84 M USD
Jan 1, 2023
-27.49 M USD
Jan 1, 2024
-77.56 M USD
Jan 1, 2025
-15.94 M USD
The Nanobiotix EBITDA history
YEAREBITDAYoY
-15.94 MUSD-79.45%
-77.56 MUSD+182.18%
-27.49 MUSD-46.98%
-51.84 MUSD-13.05%
-59.63 MUSD+44.34%
-41.31 MUSD-22.13%
-53.05 MUSD+55.58%
-34.10 MUSD+15.25%
-29.59 MUSD+19.38%
-24.78 MUSD+27.49%
-19.44 MUSD+78.19%
-10.91 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Nanobiotix Stock analysis

What does Nanobiotix do? Nanobiotix, based in Paris, France, is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and unmet medical needs. Its lead product, NBTXR3, uses hafnium oxide nanoparticles to treat various cancers, including sarcoma and lung cancer. The company has a partnership with Lian Oncology for development and commercialization in Asia. Listed on the stock market in December 2020, Nanobiotix employs 97 people. Nanobiotix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Nanobiotix stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nanobiotix is -15.94 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Nanobiotix changed from -77.56 M USD to -15.94 M USD, representing a -79.45% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Nanobiotix since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Nanobiotix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Nanobiotix

All Key Metrics — Nanobiotix